

Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation

Joanna Sułowicz¹, Anna Wojas-Pelc¹, Ewa Ignacak², Katarzyna Krzanowska², Marek Kuźniewski², Władysław Sułowicz²

¹Department of Dermatology, Jagiellonian University Medical College, Krakow, Poland

²Department of Nephrology, Jagiellonian University Medical College, Krakow, Poland

Adv Dermatol Allergol 2017; XXXIV (2): 138–142

DOI: <https://doi.org/10.5114/ada.2017.67078>

Abstract

Introduction: Kidney transplant (KTx) patients on immunosuppressive therapy are predisposed to the development of infections and cancers.

Aim: To compare the incidence and type of malignant skin lesions in kidney transplant patients and the dialyzed population based on the initiated dermatologic screening.

Material and methods: The study included 598 patients: 486 kidney transplant recipients and 112 patients on maintenance dialysis. All the patients underwent dermatological examination. Only histologically confirmed cancers were included in this study. Age, gender and immunosuppressive therapy administration were also considered. Patients were followed up by a dermatologist for a period of 5 years.

Results: Fifty-eight skin cancers; 39 basal cell carcinomas (BCC), 13 squamous cell carcinomas (SCC), 1 Bowen disease, 2 Kaposi sarcoma, 1 malignant melanoma, 1 Merkel cell carcinoma, and 1 fibrosarcoma protuberans were diagnosed in 30 (6.2%) kidney transplant patients, and 8 lesions (7 BCC and 1 SCC) were found in 4 (3.6%) patients on dialysis.

Conclusions: The initiated dermatologic screening program indicates that the risk of skin cancer incidence in post kidney transplant patients receiving immunosuppressive therapy was significantly higher than in patients on dialysis.

Key words: dialysis, kidney transplantation, immunosuppression, skin cancer.

Introduction

The population of kidney transplant (KTx) recipients is particularly vulnerable to the development of infectious complications and tumors due to the prolonged use of immunosuppressive drugs [1–3]. Skin tumors represent up to 50% of all malignancies and their incidence is depended on the geographic region and increases with time from transplantation [4–7]. According to the available literature, the most commonly occurring skin cancers are squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), known collectively as non-melanoma skin cancers (NMSC). In post-transplantation patients, the risk of BCC is 10 times higher and the risk of SCC is up to 250 times higher than in the general population [8]. In case of malignant melanoma (MM), the corresponding risk is up to 8 times higher [9], while for Kaposi's sarcoma (KS) it is up to 20 times higher [10–12].

A limited amount of publications regarding the incidence of malignancies in patients on dialysis and barely

any comparative studies of this population to a group of kidney transplant recipients can be found in the available literature [13–15].

Aim

The study was aimed to compare the incidence as well as type of malignant skin lesions in KTx patients treated with immunosuppression and in patients on maintenance dialysis therapy based on the initiated dermatologic screening program.

Material and methods

The study was conducted among a group of 598 patients on renal replacement therapy. A total of 486 patients: 296 (60.9%) men and 190 (39.1%) women aged 46.0 ± 13.1 years (range: 18–74 years) underwent KTx from a deceased donor. Within the analyzed group, 480 pa-

Address for correspondence: Joanna Sułowicz MD, PhD, Chair and Department of Dermatology, Jagiellonian University Medical College, 8 Skawińska St, 31-066 Krakow, Poland, phone: +48 12 4305266/7400, fax: +48 12 4305266/7422, e-mail: sulowiczj@interia.pl

Received: 20.10.2015, **accepted:** 5.04.2016.

tients have undergone one transplant, and 6 had two KTx. The mean time from the transplantation procedure to the time of the first dermatological examination was 54.7 ±48.8 months (median: 42.5, range: 0–298 months).

The most commonly used immunosuppressive regimens were the combinations including: cyclosporine A (CyA), mycophenolate mofetil (MMF) and steroids – 207 (42.5%) patients, tacrolimus (TAC) with MMF and steroids – 102 (20.9%), CyA with azathioprine (AZA) and steroids – 53 (10.9%) patients, CyA + steroids – 27 (5.6%), and TAC + steroids – 25 (5.1%).

Acute rejection occurred in 85 (17.5%) patients. All of these 85 patients were treated with Solumedrol, while OKT3 and ATG were additionally used in 6 and 4 cases, respectively.

The dialysis group consisted of 112 patients: 57 (50.9%) men and 55 (49.1%) women aged 57.4 ±15.4 years (ranging: 22–91 years old) who have not received immunosuppressive therapy prior to dialysis. The average time from initial dialysis to dermatological examination was 63.2 ±74.0 months. Within this group, 87 (77.7%) patients were treated with hemodialysis (HD), while 25 (22.3%) patients with peritoneal dialysis.

The study was approved by the Bioethics Committee of the Jagiellonian University (No. KBET/100/B/2006 dated June 29, 2006).

During the first dermatological evaluation, the patient's entire skin surface was carefully examined for all abnormalities. Only histologically confirmed cancers were included in the study. Patients were then followed up for a period of 5 years.

The study was retrospective-prospective.

Statistical analysis

The obtained results were statistically analyzed using the Student's *t*-test, Mann-Whitney, χ^2 and Fisher tests.

In all of the above tests, the results were statistically significant at *p* < 0.05. Statistical analysis was performed using the Statistica 9.0 software (StatSoft).

Results

In the study population of 486 KTx recipients, skin cancers were diagnosed in 30 patients (Table 1). The most commonly observed skin cancers were NMSC; overall 53 lesions were diagnosed (Table 2). Besides the NMSC we found 2 cases of Kaposi sarcoma, one Merkel cell carcinoma, one malignant melanoma and one fibrosarcoma protuberans. The ratio of BCC : SCC was 2.79, while the ratio of SCC : BCC equaled 0.36 – for the entire population of patients after KTx.

In the group of post-KTx patients, single tumors were present in 11/25 (44.0%) patients with NMSC – BCC in 7/18 patients (38.9%), and SCC in 4/10 (40.0%) patients (*p* = 1.0).

Among the KTx recipients with NMSC, BCC was diagnosed in 15 (60%) of patients, SCC in 7 (28.0%), and 3 (12.0%) patients had both types.

In 5 patients, multiple skin lesions were diagnosed during a single visit, while in other cases, numerous changes were observed after an average of 24 months (range: 2–60 months).

Among the dialyzed group, only 8 NMSC were found in 4 (3.6%) patients. Three men and one woman were diagnosed to have 7 cases of BCC and one case of SCC (Table 2). Only single tumors were observed. The ratio of BCC : SCC was 7 : 1, and SCC : BCC = 0.14 for the entire population of patients on dialysis. All of these patients were treated with hemodialysis.

In both groups, NMSC were mainly localized on the face. The mean age at the time of the first skin cancer diagnosis was lower in KTx recipients than in dialysis therapy patients (59.0 ±8.4 vs. 66.0 ±8.5); however, the

Table 1. Number and percentage of patients from both studied groups with consecutive skin cancers types

Type of changes	Patients after transplantation (N = 486)	Dialyzed patients (N = 112)	P-value*	Odds ratio** (95% of confidence)
All skin cancers	30 (6.2%)	4 (3.6%)	0.3	6.65 (1.45–30.4)
NMSC:	25 (5.1%)	4 (3.6%)	0.5	6.64 (1.25–35.2)
BCC	18 (3.7%)	4 (3.6%)	0.9	6.22 (0.94–41.1)
SCC	10 (2.1%)	1 (0.9%)	0.7	5.42 (0.43–68.1)
Bowen disease	1 (0.2%)	0	–	–
Merkel cell carcinoma	1 (0.2%)	0	–	–
Malignant melanoma	1 (0.2%)	0	–	–
Kaposi sarcoma	2 (0.4%)	0	–	–
Fibrosarcoma protuberans	1 (0.2%)	0	–	–

* χ^2 test (df = 1), **odds ratio for transplant and dialysis patients.

Table 2. Numbers and percentages of neoplastic skin changes

Type of changes	Neoplastic changes in kidney transplant patients (N = 58)	Neoplastic changes in dialyzed patients (N = 8)	P-value*
NMSC:	53 (91.4%)	8 (100%)	1.0
BCC	39 (67.2%)	7 (87.5%)	0.7
SCC	13 (22.4%)	1 (12.5%)	0.7
Bowen disease	1 (1.7%)	0	–
Merkel cell carcinoma	1 (1.7%)	0	–
Malignant melanoma	1 (1.7%)	0	–
Kaposi sarcoma	2 (3.4%)	0	–
Fibrosarcoma protuberans	1 (1.7%)	0	–

*Fisher's test.

KTx recipients were younger and the observed differences were not statistically significant ($p = 0.14$). The majority of the NMSC lesions in KTx patients (51/53 = 96.2% change), and all of the lesions in patients on dialysis were diagnosed in subjects aged 50 years and older.

In the group of KTx patients, the first diagnosis of NMSC occurred 2–170 months (median: 74 months) post-transplant surgery and this time did not differ significantly between BCC and SCC ($p = 0.7$). In the group of dialysis patients, the median time from the start of renal replacement therapy to the diagnosis of the first BCC was 77 months and 132 months for SCC.

Discussion

The available literature data indicate that the most frequently observed skin cancers among patients after KTx are SCC and BCC [12, 16, 17]. Imko, in their study of KTx patients performed in the Gdansk region, found an almost 205-fold increase in the incidence rate of skin cancers in comparison to the general population [18]. According to the available literature, the risk of post-transplantation skin cancer in the Nordic countries is up to 100 times greater than in the general population, and even up to 250 times higher in Australia, especially in the case of SCC [19, 20].

In our study, the incidence of NMSC was higher in post-transplantation patients as compared with the dialysis population. Due to the insignificant number of completed studies on skin cancers comparing dialyzed and post-transplant patients, we encountered difficulties in concluding whether other studies corroborate our results [14, 21, 22]. Although the increased incidence of NMSC in patients with transplanted organs is well documented, there are limited data on skin cancer in dialyzed patients [16, 23]. In a study by Birkeland *et al.* [13], patients on dialysis and post-KTx had a higher incidence of skin cancer as compared to the general population. We observed

non-significant differences in patients' age between the two groups ($p = 0.14$) at the time of the first skin cancer diagnosis. The mean age of post-transplant patients at the time of first diagnosis of skin cancer was 59.0 ± 8.4 and did not differ from the mean age of the patients included in the study by the Czech researchers; however, it was higher than the age of the patients seen in Imko's study and in studies by other authors [16, 18, 24, 25].

In our study, more than one new case of skin cancer was diagnosed in 56% of patients with NMSC. Similar results were obtained in the studies conducted by the Expert Group on Renal Transplantation [26]; while in Imko's study, only 22.5% of patients had multiple lesions [18]. The development of new lesions was observed to occur approximately 24 months (range: 2–60 months) later than in other studies, where new changes occurred on average only after 5 months [18, 27]. Unlike most studies by other authors [19, 28], we showed a higher incidence of BCC compared to SCC, and gender neutrality against the incidence of skin cancers in KTx patients. Results similar to ours were also obtained by a Spanish group [29].

The incidence of KS in the post-transplant group of patients is 80–500 times higher than in the general population [12, 30]. The highest incidence is seen in Saudi Arabia – 5.2% of transplant recipients [12], while in the United States the incidence does not exceed 0.5% [31]. No accurate data exist on the occurrence of KS in the Polish transplant recipients. In our group of 486 patients who underwent KTx, we observed two cases of KS (0.41%), while in another retrospective-prospective Polish study from Gdansk, involving a group of 830 renal transplant patients, no single case of KS was found [18]. In the available literature, similarly to our study, KS is more likely to develop in males [12]. Lesions were observed 2 and 9 months post-transplantation, consistently with previous observations which showed that most of the changes appear within 2 years after transplantation [30, 32].

In comparison to the results of a study by Piselli *et al.* [30], in which patients' age in cases of KS ranged from 40 to 59 years, the patients in our study were older, with average age of 51 years. In 60–90% of KS cases, the lesions are restricted to the skin [33, 34], which was confirmed by the results of our research. In case of internal organ involvement, which was not observed in this study, the changes are most commonly localized in the lymph nodes, gastrointestinal tract and lungs [35].

The available literature still questions whether there is an increased risk of malignant melanoma (MM) in post-organ transplantation patients. To date, in the largest study performed by Lindelöf *et al.* [20] during a 24-year observation period of 5,356 patients, only 6 cases of MM were diagnosed. Based on these findings, it is considered that the risk of MM in transplant patients is comparable to that of the general population. However, according to other authors, the risk is 2–8 times higher [9, 18, 19, 28]. In our study group, we identified only one case of MM, which accounted for 0.2% of all patients. Analysis of 89 cases of MM in patients from 14 transplant centers working together in the SCOPE (Skin Care in Organ Transplant Recipients, Europe) showed that the average time from organ transplantation to the development of MM was 8.7 years. In our patient, the lesion was found on the left lower extremity, at the age of 58 years, 10 years after transplantation.

There are no conclusive data determining the incidence of MCC in post-transplant patients in the available literature [36]. In a study of 10,955 patients after transplantation conducted by the Cincinnati Transplant Tumor Registry (CTTR), MCC was diagnosed in 0.37% of patients [37], whereas in our group in 0.2%, and in other studies, it occurred in 0.085% [38] and 0.071% [36] of patients.

According to the literature, MCC appeared on average seven years post transplantation (0.4–25 years) and was usually localized on the skin exposed to sunlight [37–39]. In our case, MCC was diagnosed in a 61-year-old female, at 15 months post KTx and was localized on the buttocks. The time from the appearance of the lesion to the distant metastases (liver and periaortic lymph nodes) and patient's death was over 9 months.

Fibrosarcoma protuberans occurred in a 17-year-old male at the permanent catheter exit site. Fibrosarcoma protuberans localization, as previously described in the literature, at the arterio-venous fistula can support the hypothesis that an injury may play a role in the pathogenesis of this disease [40].

Conclusions

The conducted study demonstrated a significantly higher occurrence of skin cancers among transplant recipients as compared to dialyzed patients. Interestingly, after analyzing the number of cases of particular types of skin cancer in patients receiving immunosuppression, in

contrast to most previously published papers from Western Europe and Australia, we found a higher incidence of basal-cell carcinoma than squamous-cell carcinoma.

Our study confirmed that the initiated dermatological screening program among patients on renal replacement therapy is very helpful for early diagnosis of neoplastic skin lesions. This seems particularly important in the view of the constantly growing number of organ transplant patients.

Conflict of interest

The authors declare no conflict of interest.

References

- Rodríguez-Acosta ED, Calva-Mercado JJ, Alberú-Gómez J, et al. Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital. *Gac Med Mex* 2015; 151: 20-6.
- Tessari G, Naldi L, Boschiero L, et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. *Am J Transplant* 2013; 13: 214-21.
- Wisgerhof HC, van der Geest LG, de Fijter JW, et al. Incidence of cancer in kidney transplant recipients: a long-term cohort study in a single center. *Cancer Epidemiol* 2011; 35: 105-11.
- Einollahi B, Nemeti E, Leksan-Pezeshki M, et al. Skin cancer after renal transplantation: results of a multicenter study in Iran. *Ann Transplant* 2010; 15: 44-50.
- Hwang JK, Moon IS, Kim JI. Malignancies after kidney transplantation: a 40-year single-center experience in Korea. *Transpl Int* 2011; 24: 716-21.
- Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. *Eur J Surg Oncol* 2001; 27: 409-13.
- Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. *Transplantation* 2010; 89: 1231-8.
- Stockfleth E, Ulrich C, Meyer T, et al. Skin diseases following organ transplantation – risk factors and new therapeutic approaches. *Transplant Proc* 2001; 33: 1848-53.
- Le Mire L, Hollywood K, Gray D, et al. Melanoma in renal transplant recipients. *Br J Dermatol* 2006; 154: 472-7.
- Campistol JM, Albanell J, Arns W, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. *Nephrol Dial Transplant* 2007; 22 (Suppl 1): i36-41.
- Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients – the impact of proliferation signal inhibitors. *Nephrol Dial Transplant* 2007; 22 (Suppl 1): 17-22.
- Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. *Am J Med* 1988; 84: 225-32.
- Birkeland SA, Løkkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. *Lancet* 2000; 355: 1886-7.
- Fischereder M. Cancer in patients on dialysis and after renal transplantation. *Nephrol Dial Transplant* 2008; 23: 2457-60.
- Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution:

- comparison with normal population and with patient under dialytic treatment. *Clin Transplant* 1996; 10: 461-9.
16. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excess cancer in dialysis and transplantation. *Nephrol Dial Transplant* 2009; 24: 3225-31.
 17. Savoia P, Stroppiana E, Cavaliere G, et al. Skin cancers and other cutaneous diseases in renal transplant recipients: a single Italian center observational study. *Eur J Dermatol* 2011; 21: 242-7.
 18. Imko-Walczyk B. Valuation of menace of neoplastic diseases and possibilities of its prevention in kidney transplant patients [Polish]. Doctoral thesis. Gdansk 2009.
 19. Bouves Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland Australia. *Transplantation* 1996; 61: 715-21.
 20. Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. *Br J Dermatol* 2000; 143: 513-9.
 21. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. *Lancet* 1999; 354: 93-9.
 22. Miach PJ, Dawborn JK, Xipell J. Neoplasia in patients with chronic renal failure on long-term dialysis. *Clin Nephrol* 1976; 5: 101-4.
 23. Mackenzie KA, Wells JE, Lynn KL, et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. *Nephrol Dial Transplant* 2010; 25: 300-6.
 24. Imko-Walczyk B, Ankudowicz A, Jaśkiewicz J, et al. Skin cancer in organ transplant recipients [Polish]. *Przegl Dermatol* 2011; 98: 91-103.
 25. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002; 47: 1-17.
 26. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Cancer risk after renal transplantation. Skin cancer prevention and treatment. *Nephrol Dial Transplant* 2002; 17: 31-6.
 27. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. *Transplantation* 2006; 81: 1093-100.
 28. Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. *Br J Dermatol* 2006; 154: 498-504.
 29. Bernat Garcia J, Morales Suarez-Varela M, Vilata JJ, et al. Risk factors for non-melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region. *Acta Derm Venerol* 2013; 93: 422-7.
 30. Piselli P, Busnach G, Citterio F, et al. Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4,767 recipients in Italy, 1970-2006. *Transplant Proc* 2009; 41: 1227-30.
 31. Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). *Int J Cancer* 2006; 119: 2685-91.
 32. Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. *Eur J Dermatol* 2006; 16: 553-7.
 33. Bencini PL, Montagnino G, Citerio A, et al. Cutaneous abnormalities in uremic patients. *Nephron* 1985; 40: 316-21.
 34. Bętkowska-Prokop A, Sułowicz J, Sobaszek-Pitas M, Sułowicz W. Kaposi's sarcoma in solid organ recipients. *Przegl Lek* 2010; 67: 475-8.
 35. El-Agroudy AE, El-Baz MA, Ismail AM, et al. Clinical features and course of Kaposi's sarcoma in Egyptian kidney transplant recipients. *Am J Transplant* 2003; 3: 1595-9.
 36. Koljonen V, Kukko H, Tukiainen E, et al. Incidence of Merkel cell carcinoma in renal transplant recipients. *Nephrol Dial Transplant* 2009; 24: 3231-5.
 37. Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. *Transplantation* 1999; 68: 1717-21.
 38. Kanitakis J, Euvrard S, Chouvet B, et al. Merkel cell carcinomas developing in organ transplant recipients: report of two cases with unusual histological features and literature review. *J Cutan Pathol* 2006; 33: 686-94.
 39. Buell JF, Trofe J, Hanaway MJ, et al. Immunosuppression and Merkel cell cancer. *Transplant Proc* 2002; 34: 1780-1.
 40. Piciotto F, Basolo B, Massara C, et al. Dermatofibrosarcoma protuberans at the site of arteriovenous fistula in renal transplant recipients. *Transplantation* 1999; 68: 1074-5.